Formulated IGF-I Composition
US5681814A · kind A · utility
19Cited by
5References
8Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 4, 1993 |
| Grant date | Oct 28, 1997 |
| Priority date | — |
| Expiry date | Jun 4, 2013 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K47/26
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A formulation for IGF-I is disclosed that is useful in treating hyperglycemic disorders and, in combination with growth hormone, in enhancing growth of a mammal. Also disclosed is a process for preparing a formulation of growth hormone and IGF-I from the IGF-I formulation. The IGF-I formulation comprises about 2-20 mg/ml of IGF-I, about 2-50 mg/ml of an osmolyte, about 1-15 mg/ml of a stabilizer, and a buffered solution at about pH 5-5.5, optionally with a surfactant.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.